News

Find News

Filter articles

Applied Filters

Showing 1001 to 1010 of 1033 results

Federal Circuit holds Novo Nordisk patent invalid

US21-06-2013Legal developments

The US Court of Appeals for the Federal Circuit concluded on June 18 that Novo Nordisk’s patent covering diabetes treatment repaglinide is invalid.

European Commission targets alleged ‘pay-for-delay’ with pharma fines

EU20-06-2013

The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.

US Supreme Court backs ‘rule-of-reason’ for pay-for-delay

US17-06-2013

A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.

Teva and Sun stung by $2 billion settlement

US14-06-2013

Generic drug-makers Teva Pharmaceutical and Sun Pharmaceutical have agreed to pay a combined $2.15 billion to settle a patent infringement case over Pfizer’s heartburn drug Protonix.

IPAB sets aside Sutent patent rejection

India07-06-2013

India’s Intellectual Property Appellate Board has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.

Shire settles with Teva over ADHD drug

US04-06-2013

Drug-maker Teva must wait until 2015 before selling generic versions of Shire’s Intuniv product, according to a patent settlement between the companies.

Takeda sues generics over heartburn drug

US31-05-2013

Japanese pharma company Takeda has sued generic drug-makers Impax and Sandoz for allegedly infringing a patent directed to its anti-heartburn drug Dexilant.

Actavis to buy Warner Chilcott

Ireland, US22-05-2013

Actavis announced on May 20 it will acquire specialty pharmaceutical company Warner Chilcott plc in a deal worth an estimated $5 billion.

IP key to US biosimilars success – report

US15-05-2013

Strong IP knowledge is one of four key factors to succeeding in the burgeoning US biosimilars market, according to an industry report.

AstraZeneca loses Seroquel appeal

UK10-05-2013

The UK Court of Appeal has upheld the High Court’s decision that AstraZeneca’s patent for a sustained release formulation of anti-psychotic drug quetiapine is invalid.

Showing 1001 to 1010 of 1033 results

LSIPR